<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374360</url>
  </required_header>
  <id_info>
    <org_study_id>M07-001</org_study_id>
    <nct_id>NCT01374360</nct_id>
  </id_info>
  <brief_title>Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry</brief_title>
  <official_title>Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a collection of data to evaluate safety and characterize progression of
      Paroxysmal Nocturnal Hemoglobinuria (PNH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Collection of data to evaluate safety and characterize progression of Paroxysmal Nocturnal
      Hemoglobinuria (PNH).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2007</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate safety data specific to the use of Soliris</measure>
    <time_frame>Ongoing (up to 13 years)</time_frame>
    <description>Primary analyses will assess safety endpoints, including occurrence and time to first event for the following: meningococcal infections, infections with serious outcomes, formation of human anti-drug antibodies (ADA) to Soliris, malignancy, thrombotic events, pulmonary hypertension, impaired renal function, impaired hepatic function, hemolysis, pregnancies, lactation, infusion reactions, bone marrow transplant, serious adverse events, and mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect data to characterize the progression of PNH as well as clinical outcomes, mortality and morbidity in Soliris and non-Soliris treated patients</measure>
    <time_frame>Ongoing (up to 13 years)</time_frame>
    <description>Secondary analyses will include descriptions of patient populations, PNH specific treatments, concomitant medications, progression of disease, PNH clone sites, clinical symptoms, and clinical outcomes.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <arm_group>
    <arm_group_label>Receiving Soliris</arm_group_label>
    <description>PNH patients of any age, including minors, that are receiving Soliris</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Not receiving Soliris</arm_group_label>
    <description>PNH patients of any age, including minors, that are not receiving Soliris</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        PNH Patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of any age, including minors, with a diagnosis of PNH or a detected PNH
             clone, including patients previously treated with Soliris and withdrawn from
             treatment. Patients who are minors must have parent/legal guardian consent and must be
             willing and able to give assent, if applicable as determined by the Ethics
             Committees/Institutional Review Boards. Upon attaining adulthood, these patients must
             be re-consented.

          -  Ability to comprehend and sign consent to have data entered in the PNH Registry.

        Exclusion Criteria:

          -  Inability or unwillingness to sign informed consent.

          -  Patients currently enrolled in an interventional clinical trial for treatment of PNH
             cannot be enrolled in the Registry at the same time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Marantz</last_name>
    <role>Study Director</role>
    <affiliation>Alexion Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Inc.</last_name>
    <email>ClinicalTrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Contact the PNH Registry at Alexion Pharmaceuticals, Inc. for worldwide locations.</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PNH Registry</last_name>
    </contact>
    <contact_backup>
      <email>ClinicalTrials@alexion.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2011</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PNH</keyword>
  <keyword>Paroxysmal Nocturnal hemoglobinuria</keyword>
  <keyword>Soliris</keyword>
  <keyword>Eculizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

